| 4Kscore | four-kallikrein panel blood test (proprietary name) |
| ADC | apparent diffusion coefficient |
| AI | artificial intelligence |
| AUA | American Urological Association |
| AUC | area under the receiver operating characteristic curve |
| BAUS | British Association of Urological Surgeons |
| Be-RALP | Belgian Robot-Assisted Laparoscopic Prostatectomy registry |
| BMI | body mass index |
| Bx | biopsy |
| CAPRA | Cancer of the Prostate Risk Assessment (score) |
| CENTRAL | Cochrane Central Register of Controlled Trials |
| CHARMS | Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies |
| CI | confidence interval |
| C-index | concordance index |
| ComBx | combined (MRI-targeted plus systematic) biopsy |
| cT | clinical T stage |
| CT | computed tomography |
| DNA | deoxyribonucleic acid |
| EAU | European Association of Urology |
| EAU-YAU | EAU Young Academic Urologists |
| EPE | extraprostatic extension |
| ExoDx EPI | ExoDx Prostate IntelliScore (urinary exosome assay) |
| FDA | (US) Food and Drug Administration |
| GG | (ISUP) Grade Group |
| GPS | Genomic Prostate Score (Oncotype DX) |
| GRADE | Grading of Recommendations, Assessment, Development and Evaluations |
| GS | Gleason score |
| HR | hazard ratio |
| IDC | intraductal carcinoma |
| IQR | interquartile range |
| ISUP | International Society of Urological Pathology |
| MLM | machine-learning model |
| mpMRI | multiparametric magnetic resonance imaging |
| MRI | magnetic resonance imaging |
| MRI-FIRST | MRI-FIRST randomized trial |
| MUSIC | Michigan Urological Surgery Improvement Collaborative |
| NCCN | National Comprehensive Cancer Network |
| NCI | (USA) National Cancer Institute |
| NLR | neutrophil-to-lymphocyte ratio |
| NRG | NRG Oncology (cooperative trials group) |
| OR | odds ratio |
| PANDA | Prostate cANcer graDe Assessment (challenge) |
| PCA3 | prostate cancer antigen 3 |
| PHI(D) | Prostate Health Index (Density) |
| PI-RADS | Prostate Imaging–Reporting and Data System |
| PICOTS | Population, Index prognostic factor, Comparator, Outcome, Timing, Setting (review framework) |
| PNI | perineural invasion |
| PRIMARY | PRIMARY score (intraprostatic PSMA-PET assessment) |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PRISMA-P | PRISMA for Protocols |
| PROBAST | Prediction model Risk Of Bias Assessments Tool |
| PROMIS | PROstate MR Imaging Study trial |
| PROSPERO | International Prospective Register of Systematic Reviews |
| PSA/PSAD | prostate-specific antigen/PSA density |
| PSMA | prostate-specific membrane antigen |
| PSMA-PET | PSMA positron emission tomography |
| pT | pathological T stage |
| QUADAS-2 | Quality Assessment of Diagnostic Accuracy Studies, version 2 |
| QUIPS | Quality In Prognosis Studies (tool) |
| RARP | robot-assisted radical prostatectomy |
| RP | radical prostatectomy |
| RTOG | Radiation Therapy Oncology Group |
| SEER | Surveillance, Epidemiology, and End Results (program) |
| SelectMDx | urinary biomarker assay (proprietary name) |
| SMD | standardized mean difference |
| SUVmax | maximum standardized uptake value |
| SWiM | Synthesis Without Meta-analysis (reporting guideline) |
| TRIPOD | Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis |
| TRIPOD+AI | TRIPOD+Artificial Intelligence extension |
| TRUS | transrectal ultrasound |
| TRUS-Bx | transrectal ultrasound-guided biopsy |
| UK | United Kingdom |
| USA | United States of America |